Vol 3: Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimers and other neurodegenerative diseases.Report as inadecuate



 Vol 3: Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimers and other neurodegenerative diseases.


Vol 3: Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimers and other neurodegenerative diseases. - Download this document for free, or read online. Document in PDF available to download.

Download or read this book online for free in PDF: Vol 3: Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimers and other neurodegenerative diseases.
This article is from Translational Psychiatry, volume 3.AbstractLatrepirdine DimebonTM was originally marketed as a non-selective antihistamine in Russia. It was repurposed as an effective treatment for patients suffering from Alzheimers disease AD and Huntingtons disease HD following preliminary reports showing its neuroprotective functions and ability to enhance cognition in AD and HD models. However, latrepirdine failed to show efficacy in phase III trials in AD and HD patients following encouraging phase II trials. The failure of latrepirdine in the clinical trials has highlighted the importance of understanding the precise mechanism underlying its cognitive benefits in neurodegenerative diseases before clinical evaluation. Latrepirdine has shown to affect a number of cellular functions including multireceptor activity, mitochondrial function, calcium influx and intracellular catabolic pathways; however, it is unclear how these properties contribute to its clinical benefits. Here, we review the studies investigating latrepirdine in cellular and animal models to provide a complete evaluation of its mechanisms of action in the central nervous system. In addition, we review recent studies that demonstrate neuroprotective functions for latrepirdine-related class of molecules including the β-carbolines and aminopropyl carbazoles in AD, Parkinsons disease and amyotrophic lateral sclerosis models. Assessment of their neuroprotective effects and underlying biological functions presents obvious value for developing structural analogues of latrepirdine for dementia treatment.



Author: Bharadwaj, P R; Bates, K A; Porter, T; Teimouri, E; Perry, G; Steele, J W; Gandy, S; Groth, D; Martins, R N; Verdile, Giuseppe

Source: https://archive.org/







Related documents